Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients

  • Gamida Cell Ltd (NASDAQ:GMDA) announced that updated infection data on omidubicel compared to umbilical cord blood transplantation (UCB) was shared at the Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings.
  • The data from a sub-study of the Phase 3 trial of omidubicel showed early and enhanced recovery of various immune cells, including circulatory dendritic cell subtypes, NK cells, and CD4+ T cells within the first 28 days.
  • Related: Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings.
  • The recovery was sustained from Day 28 onwards, and such immune recovery was associated with lower rates of severe infection. 
  • Gamida Cell initiated a rolling Biologics License Application (BLA) submission for omidubicel in Q1 of 2022 and is on track to complete the submission of all modules of the BLA in Q2 2022.
  • Price Action: GMDA shares are down 8.17% at $2.47 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.